Retrospective Brazilian Study of Fulvestrant in Advanced Breast Cancer

AstraZeneca

Status: Completed

Conditions: Breast Cancer

Treatments: Drug: Fulvestrant

Study type: Observational

Funder types: Industry; Other

Identifiers

NCT00660803

NIS-OBR-FAS-2007/1

Details and patient eligibility

About

Characterize the demographic and clinical features, as well as the main treatment results, among patients with advanced breast cancer treated with fulvestrant in Brazil.

Enrollment: 200 estimated patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Positive HR or ER by immunohistochemistry
• Postmenopausal status at the time of treatment with fulvestrant
• Failure of at least one previous endocrine therapy before treatment with fulvestrant.

Exclusion criteria

• Patients who are still undergoing treatment with fulvestrant will not be eligible to participate in the study

Trial design

200 participants in 1 patient group

1

Description:

Postmenopausal women with hormone-receptor positive, advanced breast cancer who have failed at least one previous endocrine therapy and who have been treated at any one of the participating centres with fulvestrant.

Treatment:

Drug: Fulvestrant